The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 6-4 that a clinical trial failed to prove the drug is effective in patients with ALS.
The FDA is not required to follow the committee’s recommendations and is expected to make a final decision on the drug’s approval status by June 29.
Editor’s note: This article was updated March 31 at 5:24 p.m.
